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Hepatic lipase treatment of chylomicron remnants
increases exposure of apolipoprotein E
Dawn L. Brasaemle,' Kathleen Cornely-Moss,' and And& Bensadoun3
Division of Nutritional Sciences and Division of Biological Sciences, Cornel1 University, Ithaca, NY 14853
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Dietary lipids are packaged into chylomicrons in intestinal epithelial cells. Nascent chylomicrons are large
( > 1000 A) triglyceride-rich lipoproteins containing
apolipoprotein A-I (apoA-I), apoA-IV, and apoB-48
(reviewed in refs. 1 and 2). Chylomicrons are secreted
into the lymph and enter the general circulation after passage through the thoracic duct. Circulating chylomicrons
acquire apoC-I1 which acts as a co-factor for lipoprotein
lipase. Lipoprotein lipase associated with endothelial cell
surfaces of capillary beds hydrolyzes a large portion of
triglyceride in the lipoprotein core. This lipolysis leads to
remodeling of the lipoprotein characterized by loss of both
core and excess surface components. The resulting
chylomicron remnant acquires apoE from circulating
lipoproteins.
Chylomicron remnants are removed from the circulation primarily by the liver, and by bone marrow and
spleen in some species (3, 4). Clearance of chylomicron
remnants is mediated by interaction of apoE on the
lipoprotein surface with specific cell surface receptors
(5-9).
Hepatic lipase appears to play a role in the metabolism
of triglyceride-rich lipoproteins. Several examples of
heritable hepatic lipase deficiency in humans have been
described (10-17). Common features among these subjects
include elevated fasting serum triglyceride levels and the
accumulation of triglyceride-enriched remnant particles
isolated by centrifugation from the density ranges of intermediate density lipoproteins and low density lipoproteins.
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Abstract The consequences of hepatic lipase treatment of
chylomicron remnants were studied. Rats were fed corn oil to induce production and secretion of chylomicrons and were then
injected with polyclonal antiserum raised against hepatic lipase
to specifically and quantitatively inhibit hepatic lipase activity in
vivo. A fraction enriched in chylomicron remnants was isolated
from rat plasma by a brief centrifugation step that preferentially
isolates triglyceride-rich apolipoprotein (apo) B-48-containing
lipoproteins. The chylomicron remnants were then treated with
hepatic lipase in vitro, or incubated under identical conditions
in the absence of enzyme (control incubations). Hepatic lipasetreated and control chylomicron remnants were isolated by a second brief centrifugation step using discontinuous salt gradients. Control lipoproteins were collected from one discrete
band at d < 1.02 g/ml. Hepatic lipase-treated chylomicron remnants formed two discrete bands and were collected at two densities: d<1.02 g/ml and 1.02<d<1.04 g/ml. The buoyant
(d < 1.02 g/ml) subfraction of hepatic lipase-treated chylomicron
remnants was depleted of 62% of the total phospholipid when
compared to control d < 1.02 g/ml lipoproteins. The dense
(1.02 < d <LO4 g/ml) subfraction of hepatic lipase-treated
chylomicron remnants was depleted of 65% of particle phospholipid content and 90% of particle triglyceride content when
compared to control d < 1.02 g/ml lipoproteins. The dense
(1.02 < d < 1.04 g/ml) subfraction of hepatic lipase-treated
chylomicron remnants showed 5- to 7-fold greater immunoreactivity of apoE when compared to control lipoproteins in competitive displacement immunoassays. IThese data suggest
that extensive hydrolysis of chylomicron remnant phospholipid
and triglyceride leads to the formation of a dense remnant particle that contains highly exposed apoE. This increased exposure
of apoE may be the key to the previously observed increased
degradation of chylomicron remnants treated with hepatic lipase
because more exposed apoE may bind better to cell surface
lipoprotein receptors. Furthermore, the data imply that hepatic
lipase cleaves chylomicron remnant phospholipid and triglyceride in a sequential fashion; hydrolytic intermediates depleted
only of phospholipid precede the formation of a smaller dense
remnant particle depleted of phospholipid and triglyceride. Brasaemle, D. L., K. Cornely-Moss, and A. Bensadoun.
Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E. J. Lipid Res. 1993. 34: 455-465.

MATERIALS AND METHODS

Preparation of antiserum against rat apoE and anti-rat
apoE immunoglobulin preparation
ApoE was purified from rat d <1.04 g/ml lipoproteins
following methods adapted from previously published
procedures (29, 30). Antiserum to purified rat apoE was
raised in a goat. Goat anti-rat apoE immunoglobulins
were purified from antisera by affinity chromatography
using an apoE-Sepharose@ 4B column prepared by
coupling apoE to CNBr-activated Sepharose@4B (Pharmacia) following the manufacturer's procedures.
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ELISA conditions for the determination of total apoE
concentration of lipoproteins
ApoE concentrations of lipoproteins were determined
by a sandwich ELISA using affinity-purified polyclonal
antibodies raised against rat apoE for both the capturing
antibody and the horseradish peroxidase-tagged (31) antibody. A sample buffer of 0.5 M NaCl, 1% bovine serum
albumin (BSA), 0.05% Tween 20, 10 mM sodium phosphate, pH 7.4, was used for sample and standard dilutions, and horseradish peroxidase-antibody conjugate addition. This assay gave a linear increase in absorbance at
490 nm with increasing concentrations of highly purified
apoE to 1 ng. The affinity-purified polyclonal antibody
used in this assay showed no cross reactivity to apoB; 100
ng of apoB-48 gave no detectable absorbance at 490 nm.
To maximally expose epitopes of apoE on the surface of
triglyceride-rich (d < 1.02 g/ml) lipoproteins, lipoprotein
samples (and purified apoE standards) were incubated for
1 h at 37OC in 10 mM sodium dodecyl sulfate (SDS) before further dilution and addition to the assay plates. As
SDS interferes with the detection of apoE, the final concentrations of SDS in all diluted samples and standards
were adjusted to be equal and less than or equal to 0.5 mM.

ELISA conditions for the determination of exposed
apoE on lipoprotein fractions
Exposure of apoE on the surfaces of lipoproteins was
assayed using a competitive displacement immunoassay.
Alternate rows of 96-well ELISA plates were coated with
purified rat apoE; alternate rows were coated with buffer
containing no apoE, to serve as controls for nonspecific
binding. Serial dilutions of lipoproteins were made in 3 %
BSA, phosphate-buffered saline (PBS), pH 7.4. The goat
anti-rat apoE immunoglobulin-horseradish peroxidase
conjugate was diluted in 3% BSA, PBS, pH 7.4, and was
added to the serial dilutions of lipoproteins. The
lipoprotein solutions were incubated briefly on ice and
then added to both apoE-coated and control (uncoated)
wells of the ELISA plates. Soluble lipoprotein/antibody
complexes were removed by washing, and an o-phenylenediamine substrate solution was used to quantitate immunoglobulin-horseradish peroxidase complexed with
immobilized apoE.
Data were expressed as the ratio of the absorbances at
490 nm of sample wells (B) to the average absorbance at
490 nm of wells incubated with dilute goat anti-rat apoE
immunoglobulin-horseradish
peroxidase
conjugate
without competing lipoprotein (Bo). The B/Bo ratio was
then plotted as a function of the total apoE content of
lipoprotein samples determined by ELISA of SDS-treated
lipoproteins. Binding curves were analyzed simultaneously using the ALLFIT program (1992 version developed by DeLean, A., P. J. Munson, V. Guardabasso, and
D. Rodbard, National Institutes of Health, Bethesda,

Downloaded from www.jlr.org by guest, on June 1, 2016

Additionally, hepatic lipase catalytic activity has been
blocked by injection of specific polyclonal antisera into
both fasted and lipid-fed experimental animals to yield
similar accumulations of remnant particles in plasma
(18-25). These observations suggest that hepatic lipase is
necessary to clear triglyceride-rich lipoprotein remnants
from the circulation.
The probable mechanism of hepatic lipase-assisted
metabolism of triglyceride-rich lipoproteins involves
hydrolysis of lipids in the circulating lipoproteins by the
enzyme. In vitro, hepatic lipase acts as a phospholipase
and a hydrolase of neutral glycerides in a number of
model systems including isolated lipoproteins (reviewed
in refs. 26 and 27). Hepatic lipase is synthesized in
hepatocytes and, after secretion, binds to endothelial cell
surfaces in liver, adrenal gland, and ovary (reviewed in
ref. 28). From these locations, it comes into contact with
circulating lipoproteins; ensuing hydrolysis of phospholipids and triglycerides may increase the exposure of
apolipoproteins essential for receptor-mediated uptake of
the lipoproteins.
The purpose of this study was to examine the consequences of hepatic lipase-catalyzed hydrolysis of
chylomicron remnant lipids and to test the hypothesis that
this activity of hepatic lipase increases the immunoreactivity of apoE on chylomicron remnants. We collected
triglyceride-rich lipoproteins from corn oil-fed rats injected with polyclonal antibodies raised against hepatic lipase to block enzyme activity. The collected lipoproteins
were thus subjected to lipolysis by lipoprotein lipase in
vivo, but not to hydrolysis by hepatic lipase. A portion of
the collected lipoproteins was treated with hepatic lipase
in vitro; the remaining lipoproteins were incubated under
identical conditions in the absence of enzyme. The lipid
and apolipoprotein contents of hepatic lipase-treated and
untreated (control) lipoproteins were compared. Hepatic
lipase-treated chylomicron remnants were found to contain more immunoreactive apoE relative to total apoE
than untreated lipoproteins; hence, hepatic lipase treatment inc~asedthe exposure of apoE on Chylomicron remnants.

MD) on an IBM-PC; this program fits families of sigmoidal curves using the four-parameter logistic equation (32).
Slopes of fitted curves and midpoint values of binding
isotherms (EDs0) were determined.

Preparation of antiserum against rat apoB-100 and
anti-rat apoB-48 immunoglobulin preparation

16,900 or 29,400 pmol fatty acid released per h, as determined using a tri[3H]oleoylglycero1 substrate.

Purification of rat hepatic lipase for lipolysis of
lipoproteins in vitro

Hepatic lipase was purified from rat liver perfusate and
used to immunize a goat as described previously (34).
The titers of two antisera used in these studies were determined by the method described previously by Kompiang,
Bensadoun, and Yang (35). One ml of antiserum inhibited hepatic lipase activity at a level equivalent to

taining hepatic lipase catalytic activity were pooled and
concentrated for use in experiments by elution over a
small (1 g) heparin Sepharose@column equilibrated with
0.1% BSA, 30% glycerol, 10 mM sodium phosphate, pH
7.4. The column was washed with the column equilibration buffer, and then eluted with 1% BSA, 1.0 M NaCl,

ApoB-100 and apoB-48 were isolated from rat very low
density lipoproteins (VLDL) using the procedures of Zilversmit and Shea (33). Purified rat apoB-100 was used to
immunize a goat. Goat anti-rat apoB-48 immunoglobulin
was purified from antisera raised against apoB-100 using
an apoB-48-Affi-gel 10 column prepared by coupling
apoB-48 to Affi-gel 10 (Bio-Rad) following the manufacturer’s instructions.

ELISA conditions for the determination of total
apoB-48 concentration of lipoproteins

_ .
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ApoB concentrations of lipoproteins were determined
by a sandwich
ELISA using affinity-purified
apoB-48-specific polyclonal antibodies for both the capturing antibody and the horseradish peroxidase-tagged
(31) antibody. A sample buffer of 1% BSA, 0.025% Tween
20, PBS, p H 7.4, was used for sample and standard dilutions, and horseradish peroxidase-antibody conjugate addition. This assay gave a linear increase in absorbance at
490 nm with increasing concentrations of highly purified
apoB-48 or apoB-100 to 20 ng; the slope of the standard
curve .for apoB-100 was approximately 50% of the slope
of the standard curve for apoB-48. The affinity-purified
polyclonal antibody used in this assay showed no crossreactivity to apoE; 100 ng of apoE gave no detectable absorbance at 490 nm.
To maximally expose epitopes of apoB on the surface of
triglyceride-rich (d < 1.02 g/ml) lipoproteins, lipoprotein
samples (and purified apoB-48 standards) were incubated
for 1 h at 37OC in 5% Triton X-100 before further dilution
and addition to the assay plates. Incubation of
lipoproteins with 5% Triton X-100 was more effective at
increasing exposure of epitopes on apoB than incubation
of lipoproteins with 10 mM SDS, 1% Triton X-100, rat
hepatic lipase, or bee venom phospholipase AP. Concentrations of Triton X-100 ranging from 0.1% to 5% interfered minimally with the ability to quantitate apoB-48 by
ELISA; nevertheless, the Triton X-100 concentrations of
all samples and standards were adjusted to be equal and
less than or equal to 0.1%.

Hepatic lipase was purified from rat liver perfusate by
new methods that eliminate low levels of contaminant
apoE and apoB (Bensadoun, A., D. L. Brasaemle, J. Hsu,
and L. B. Hughes, unpublished results). Briefly, perfusate
was collected from 60 adult male rat livers and concentrated using PM30 Diaflo Ultrafiltration Membranes
(Amicon Corporation, Danvers, MA) in an Amicon concentration cell at 4OC. All subsequent steps were carried
out at 4OC.
The concentrated liver perfusate was dialyzed against
20 mM Tris, p H 7.2, and loaded onto a 1.5 cm x 11 cm
Q-Sepharosem (Pharmacia) column equilibrated with 2.5
mM n-decylsucrose (CALBIOCHEM), 20 mM Tris, p H
7.2. The column was washed extensively with 20 mM
Tris, p H 7.2, and 0.2% Triton X-100, 20 mM Tris, pH
7.2. Bound hepatic lipase was eluted with a 400-ml gradient of 0-1.0 M NaCl in 2.5 mM n-decylsucrose, 20 mM
Tris, pH 7.2. Column fractions containing enzyme activity were pooled, the buffer was adjusted to contain 20%
glycerol, and the pooled fractions were loaded onto a 2.6
cm x 31 cm heparin Sepharose@ (Pharmacia) column
equilibrated with 20 mM Tris, pH 7.2. The column was
washed extensively with 20% glycerol, 20 mM Tris, pH
7.2, and 0.1% Triton N101, 20% glycerol, 20 mM Tris,
p H 7.2. Bound hepatic lipase was eluted with a 400-ml
gradient of 0-1.2 M NaCl in 2.5 mM n-decylsucrose, 20
mM Tris, pH 7.2. Column fractions containing hepatic lipase catalytic activity were pooled and dialyzed against
2.5 mM n-decylsucrose, 20% glycerol, 10 mM sodium
phosphate, p H 7.2
Pooled and dialyzed fractions containing hepatic lipase
activity were loaded onto a 1.6 cm x 7 cm S-Sepharose@
(Pharmacia) column equilibrated with 20% glycerol, 10
mM sodium phosphate, p H 7.2. The column was washed
extensively with the column equilibration buffer, and then
eluted with a 300-ml gradient of 0-1.0 M NaCl in 2.5 mM
n-decylsucrose, 20% glycerol, 10 mM sodium phosphate,
pH 7.2. Hepatic lipase purified by these methods showed
a major band at 55,000 daltons and a faint band at 59,000
daltons in Coomassie blue R-250-stained SDSpolyacrylamide gels, and showed no contamination by
apoE or apoB as determined by ELISA. The specific ac-

30% glycerol, 10 mM sodium phosphate, pH 7.4. Concentrated hepatic lipase was stored at -8OOC before use.

Collection of chylomicron remnants

Treatment of triglyceride-rich lipoproteins with
purified rat hepatic lipase in vitro and further
isolation of remnant lipoproteins
Triglyceride-rich d < 1.02 g/ml lipoproteins were treated
with purified rat hepatic lipase in vitro for 1 h at 35°C.
Hepatic lipase was added to the lipoprotein solutions at a
level of 19-39 units of enzyme activity (pequivalents fatty
acid released from triglyceride per h) per mg lipoprotein
triglyceride. The incubation mixture contained
lipoprotein and hepatic lipase in 10 mg/ml BSA, 0.5 M
NaCl, 10 mM CaC12, 0.2 M Tris, p H 8.6. A control incubation contained all components except hepatic lipase.
Control and hepatic lipase-treated remnants were isolated by ultracentrifugation using discontinuous salt gradients. The density of each incubation mixture was adjusted to 1.08 g/ml with a salt solution containing NaCl
and NaBr, and the lipoprotein solutions were overlaid
with d 1.04 g/ml, and then d 1.02 g/ml salt solutions. The
gradients were centrifuged for 75 min at 202,000 g in a
Beckman SW40 rotor at 14°C. Lipoproteins were harvested by slicing the tubes.

Analysis of chylomicron remnant composition
The compositions of control and hepatic lipase-treated
chylomicron remnants were determined. Apolipoprotein

458

Journal of Lipid Research

Volume 34, 1993

RESULTS

Isolation of apoB-48-containing lipoproteins from
corn oil-fed rats
Triglyceride-rich lipoproteins were collected from corn
oil-fed rats with functionally inactive hepatic lipase.
These lipoproteins were, however, exposed to lipoprotein
lipase in vivo. The conditions used to collect triglyceriderich lipoproteins from corn oil-fed rats were designed to
maximize the recovery of apoB-48-containing lipoproteins
with minimal contamination of the preparation with
apoB-100-containing lipoproteins and minimal loss of
apoE. When very brief centrifugations of 25 min with a
SW40 rotor were used, d < 1.02 g/ml lipoprotein fractions
were highly enriched in apoB-48 (see Fig. 1, lane 2).
Levels of apoB-100 determined by densitometric scanning
of Coomassie Blue R-250-stained SDS-PAGE gels (33)
typically totaled less than 5% of the levels of apoB-48
(data not shown). Previous studies have documented the
secretion of apoB-48-containing lipoproteins by rat liver
as well as intestine (41-45). Although we cannot rule out
the presence of lipoproteins originating from liver in the
collected d<1.02 g/ml fraction, the feeding of a bolus of
corn oil to the rats should ensure an abundant supply of
intestinally derived chylomicron remnants in circulation.

Changes in chylomicron remnant density profiles after
hepatic lipase treatment
ApoB-48-containing d < 1.02 g/ml lipoproteins were
treated with hepatic lipase in vitro. The lipolysis reaction
was followed by isolation of the remnant products by
ultracentrifugation of salt gradients. Lipoproteins from
control incubations (no hepatic lipase) were collected in
the same density range (d<1.02 g/ml) as the original
triglyceride-rich lipoprotein. In four experiments,
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Male Long-Evans rats (Harlan Sprague-Dawley),
270-370 g, were fed commercial rat chow ad libitum
throughout the study. To increase absorbed lipid, rats
were fed 2 ml of corn oil emulsified by sonication with 5 %
sodium taurodeoxycholate in a 1:l (dv) ratio by gastric intubation. Immediately after corn oil gavage, each rat was
anesthetized with ether, and injected via the jugular vein
with 1 ml goat antiserum raised against rat hepatic lipase.
The antiserum used in this study had a titer 7- to 13-fold
higher than that previously demonstrated to specifically
and completely inhibit the activity of heparin-releasable
hepatic lipase when injected into rats (22). After 3 h, the
rats were injected with an additional 1 ml goat anti-rat
hepatic lipase serum via the jugular vein. Six h after the
corn oil gavage and initial injection of antiserum, the
animals were exsanguinated by cardiac puncture.
Triglyceride-rich, apoB-48-containing lipoproteins
were isolated from plasma by centrifugation. The density
of the collected plasma was adjusted to d = 1.04 g/ml with
a salt solution containing NaCl and NaBr; centrifuge
tubes containing this plasma were overlaid with d 1.02
g/ml salt solution and centrifuged for 25 min at 202,000
g (average) in a Beckman SW 40 rotor at 14OC.
Lipoproteins of d < 1.02 g/ml were collected by slicing the
tubes and were stored at 4OC overnight.

concentrations were determined by ELISAs within 8 h of'
lipoprotein isolation. Total phospholipid content was calculated from the total phosphorus content (36) of solvent
lipid extracts (37). Total and partial glyceride analysis was
conducted by thin-layer chromatography of lipid extracts
(37) followed by quantitation of glycerol content (38) of
mono-, di-, and triglyceride extracts from thin-layer chromatography silica gel scrapings. Total cholesterol content
(cholesterol and cholesteryl esters) was determined using
an enzymatic cholesterol assay kit from BoehringerMannheim (Kit ffl236691). Total protein content was determined by the method of Lowry et al. (39), using a BSA
standard. SDS-PAGE of lipoprotein fractions and purified
apolipoproteins was conducted using the methods of
Laemmli (40). Statistical significance of composition
differences between control and hepatic lipase-treated
chylomicron remnants were evaluated by Student's paired
t-test.

ApoBlOO

Apo E

1

2

3

4

5

92-9876 of the apoB-48 recovered from control incubation gradients was collected in this density range (Table
1). The 1.02<d<1.04 g/ml fraction of the control
lipoprotein gradients showed a very low concentration of
TABLE 1.

Recovery of apolipoproteins E and B-48 in salt density gradient fractions
Lipoprotein Density Fractions

Sample

d < 1.02 g/ml

1.02<d<1.04 g/ml

d 2 1.04 g/ml

% ofapoE recovered
Control
Hepatic lipase-treated

66
56

Control
Hepatic lipase-treated

95 f 3
66 f 7d

f
f

11
3’

2“
31

f

5

32 f 10
14 f 5‘

% of apoB-48 recovered
1”
26

f

5

4 f 4
8 f 4‘

Data are means f standard deviations for the average of duplicate ELISA analyses from four experiments.
“Average of determinations from two experiments.
*Differences between apoE recovery data of control d < 1.02 g/ml fractions and hepatic lipase-treated d < 1.02
g/ml fractions are significant at a level of P < 0.10 by Student’s paired I-test.
‘APE recovery data: control d 2 1.04 g/ml fractions vs. hepatic lipase-treated d r 1 . 0 4 g/ml fractions; P < 0.05.
dApoB-48 recovery data: control d < 1.02 g/ml fractions vs. hepatic lipase-treated d < 1.02 g/ml fractions;
P < 0.005.
' ApoB-48 recovery data; control d 2 1.04 g/ml fractions vs. hepatic lipase-treated d r 1.04 g/ml fractions;
P < 0.005.
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Fig. , l . Coomassie Blue R25O-stained SDS-PAGE gel of lipoprotein
fractions from density gradients. Lane 1 contains molecular mass standards myosin (205 kD), @-galactosidase(116 kD), phosphorylase B (97.4
kD), bovine serum albumin (66 kD), egg albumin (45 kD), and carbonic
anhydrase (29 kD). Lane 2 contains d < 1.02 g/ml lipoproteins from the
initial isolation of chylomicron remnants from plasma. Lanes 3-5 contain lipoproteins from various density fractions obtained from the centrifugal isolation of chylomicron remnants after hepatic lipase treatment.
Lane 3 contains d < 1.02 glml control lipoproteins from incubations in
the absence of hepatic lipase. Lane 4 contains 1.04< d < 1.02 g/ml dense
remnants from hepatic lipase incubations. Lane 5 contains d < 1.02 g/ml
lipoproteins from hepatic lipase incubations. Lanes 2-5 contain equal
amounts of total protein.

apoB-48. Comparison of the protein composition of
d < 1.02 g/ml lipoproteins from the control incubation
(Fig. 1, lane 3) to that of the original d<1.02 g/ml
lipoproteins (Fig. 1, lane 2) indicated a decrease in albumin content and an enrichment of the relative
apolipoprotein content of the lipoprotein fraction following the second centrifugation.
Dense chylomicron remnants were formed during the
treatment of triglyceride-rich lipoproteins with hepatic lipase. The majority of chylomicron remnants from hepatic
lipase incubations were collected from two density ranges
of the salt gradients: d<1.02 g/ml and 1.02<d<1.04
g/ml. In four experiments, 56-7376 of the apoB-48 recovered from the hepatic lipase treatment gradients was collected from the d <1.02 g/ml density range, 21-3276 from
the 1.02<d<1.04 g/ml range, and 4-1276 from the
d>1.04 g/ml range (Table 1). Comparison of the protein
composition of the hepatic lipase treatment d < 1.02 g/ml
fraction (Fig. 1, lane 5) to the control d<1.02 g/ml fraction (Fig. 1, lane 3) showed similar apolipoprotein content. The protein composition of the 1.02 < d <1.04 g/ml
fraction, “dense remnants,”(Fig. 1, lane 4) indicates an enrichment of albumin relative to apolipoproteins. The increased albumin in the dense remnant fraction originated
from BSA added to the lipolysis mixture. The addition of
albumin during lipolysis is necessary to remove monoacylglycerides, lysophosphatidylcholine, and free fatty acid
from the hydrolyzed lipoproteins (46, 47). Enrichment of
albumin in the dense remnant fraction may result from
increased affinity of the dense chylomicron remnants for
albumin or from decreased washing effects for lipoprotein
collected lower in the gradient. As the various lipoprotein
fractions contained a variable content of contaminating
albumin, comparisons of lipid content of these fractions
were made on a per particle basis using apoB-48 content
as an indicator of particle number.

Changes in chylomicron remnant lipid composition
after hepatic lipase treatment

Changes in apoE exposure and content with hepatic
lipase treatment of chylomicron remnants

The exposure of apoE on chylomicron remnants was
studied using polyclonal antibodies raised against rat
apoE in competitive displacement immunoassays. Immunoreactivity of apoE on the hepatic lipase-treated
dense subfraction of chylomicron remnants (1.02 < d <
1.04 g/ml) was greater than that of control (d < 1.02 g/ml)
lipoproteins (Fig. 2 and Table 3). The midpoints of the
binding isotherms (EDSOs)were used to compare the relative exposure of apoE in the two chylomicron remnant
subfractions (Table 3); apoE on hepatic lipase-treated
dense remnants (1.02 < d < 1.04 g/ml) was 5 - to 7-fold
more immunoreactive than apoE on control lipoproteins.
Additionally, the slopes of binding isotherms from hepatic
lipase-treated dense remnants (1.02 < d < 1.04 g/ml) were
steeper than the slopes of the control (d<1.02 g/ml)
lipoprotein binding curves (Table 3), implying increased
binding affinity of polyclonal antibodies for apoE on
hepatic lipase-treated chylomicron remnants. These data
suggest that hepatic lipase treatment increases the number of exposed epitopes on apoE for polyclonal antibody
binding and that the consequent increased binding occurs
with higher affinity.
Similar competitive displacement immunoassays were
used to compare the relative exposure of apoE on d < 1.02
g/ml hepatic lipase-treated chylomicron remnants to control (d < 1.02 g/ml) lipoproteins. In three experiments, the
ratios of EDS0values of binding isotherms of control over
hepatic lipase-treated d < 1.02 g/ml lipoproteins were 0.9,
3.6, and 3.0. Student's paired t-test analysis of EDs0values
and slopes indicated that differences between the two

TABLE 2. Lipoprotein lipid composition

Lipid Component

Control
d < 1 . 0 2 g/ml
Fraction

Hepatic
Lipase
Treatment
d < 1.02 g/ml
Fraction

Hepatic Lipase
Treatment
Dense Remnants
1.02<d<1.04 g/ml

,ug lipid/pg apoB-48
Triglyceride
Diglyceride
Monoglyceride
Total cholesterol
Phospholipid

129 i
13.0 i
4.28 f
5.81 i
18.78 i

40
6.3
2.94
1.85
4.73

*

115
9.72 i
8.65 f
5.99 i
7.10 i

26
5.12
5.26
1.61
2.40d

13.1 k 7.2"b
5.09 i 1.84
7.12 f 4.81'
5.90 + 2.14
6.56 k 3.64'

Data are the means + standard deviation for duplicate lipid analyses of four separate experiments.
"Differencesbetween control d < 1.02g/ml fractions and hepatic lipase treatment dense remnants (1.02< d < 1.04
g/ml) are significant at a level OF P < 0.01 by Student's paired t-test.
'Hepatic lipase treatment d<1.02 g/ml fractions vs. hepatic lipase treatment dense remnants; P < 0.01.
'Control d < 1.02 g/ml fractions vs. hepatic lipase treatment dense remnants; P < 0.05.
dControl d < 1.02 g/ml fractions vs. hepatic lipase treatment d < 1.02 glml fractions; P <0.05.
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Hepatic lipase hydrolyzes both surface phospholipid
and core triglyceride of chylomicron remnants. Hepatic
lipase-treated chylomicron remnants isolated at d < 1.02
g/ml showed depletion of 62% of total phospholipid relative to apoB-48 content when compared to control
(d < 1.02 g/ml) lipoproteins; triglyceride content of this
fraction was similar to control lipoproteins (Table 2).
Dense hepatic lipase-treated remnants (1.02 < d < 1.04
g/ml) showed depletion of 65% of total phospholipid and
90% of triglyceride when compared to control (d < 1.02
g/ml) lipoproteins. Therefore, the shift of a portion of
hepatic lipase-treated chylomicron remnants to the higher
density range between 1.02 g/ml and 1.04 g/ml was due to
the large decrease in particle triglyceride content in addition to depletion of phospholipid. Additionally, dense
hepatic lipase-treated chylomicron remnants showed an
increase in monoglyceride content relative to control
lipoproteins. No significant differences in total cholesterol
content per particle were observed.
Measurements of lipid composition relative to apoB
showed large variability between experiments. A potential
source of variability was a wide range of particle size of
the initial d < 1.02 g/ml lipoprotein. Triglyceride content
of control lipoproteins covered a range of 80 to 180 pg
triglyceridelpg apoB-48; thus, the starting chylomicron
remnant core size varied considerably. The degree of
hepatic lipase-catalyzed triglyceride hydrolysis of the
starting d < 1.02 g/ml lipoprotein fraction also varied between experiments. For four experiments, 21-32% of total
apoB-48 (hence, 21-32% of the particles) was recovered in
the dense remnant (1.02 < d <LO4 g/ml) subfraction of
hepatic lipase-treated lipoprotein; the triglyceride content
of this dense subfraction varied from 6 to 23 pg triglyceridelpg apoB-48. Despite experimental variability in lipid

composition measurements, the pattern for these
parameters was the same and significant differences were
observed for all four experiments.
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lipoprotein fractions were not statistically significant
(P = 0.19); hence, it is unclear whether the hydrolysis of
phospholipids observed in hepatic lipase-treated d <1.02
g/ml lipoproteins leads to increased exposure of apoE.
ApoE recovery data from lipoprotein fractions isolated
by density gradients suggest that a portion of apoE is
loosely associated with chylomicron remnants. Approximately 30% of apoE was isolated in d 2 1.04 g/ml fractions
of control lipoproteins (Table 1); apoB content of the same
fractions was very low (4% of recovered apoB). These
data imply that apoE recovered from d 5 1.04 g/ml fracTABLE 3.

Effect of heoatic lipase treatment on immunoreactivity of apoE on chylomicron remnants
Hepatic Lipase
Treatment
Dense Remnants
(1.0'2 < d C 1.04 g/ml)

Control
dc1.02 g/ml
Fraction
Experiment #

1
2
3
4
Mean
SD

*

ED50

5.27
16.84
21.83
15.23
14.79
f 6.94

Slope

0.282
0.366
0.316
0.366
0.332
0.041

EDw

f

1.10
2.42
3.08
3.04
2.41
0.92"

Slope

EDSoControll
ED,, Hepatic
Lipase
Treatment
Dense
Remnants

0.565
0.612
0.541
0.473
0.548
+ 0.058"

4.79
6.96
7.09
5.01
5.96
f 1.23

Competitive binding isotherm midpoint (ED,,) values and slopes were determined using the ALLFIT program
as described in Materials and Methods.
"Differences between control d < 1.02 g/ml fraction and hepatic lipase treatment dense remnants are significant
at a level of P < 0.05 by Student's paired t-test.
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Fig. 2. Competition by control (closed symbols) and hepatic lipasetreated (open symbols) chylomicron remnants with immobilized apoE
for binding to soluble polyclonal goat anti-rat hepatic lipase IgG conjugated to horseradish peroxidase. Lipoprotein concentration is expressed as total apoE mass determined by ELISA of SDS-treated
lipoproteins. B/Bo values represent absorbance of ELISA sample wells
containing lipoprotein/absorbance of wells containing only immobilized
apoE. Data shown are averages of duplicate values from one representative experiment out of four.

tions of control samples is not associated with
lipoproteins. In agreement with our findings, other
researchers have observed the dissociation of apoE from
lipoproteins during centrifugation (48, 49). Less apoE
was recovered in d 11.04 g/ml fractions from density gradients of hepatic lipase-treated lipoproteins than from the
same fractions of control lipoproteins; greater apoB content was measured in these dense fractions from hepatic
lipase-treated lipoproteins (compared to control
lipoproteins). These data suggest that at least some of the
apoE was associated with lipoproteins in the d 2 1.04 g/ml
fractions of hepatic lipase-treated chylomicron remnants.
Additional apoE and apoB were found at an intermediate
density (1.02 < d <1.04 g/ml) in the dense chylomicron
remnants fraction of hepatic lipase-treated lipoproteins.
Competitive displacement immunoassays were used to
determine whether apoE on the original d<1.02 g/ml
chylomicron remnants isolated after a single centrifugation step was more immunoreactive than apoE remaining
on control d <1.02 g/ml lipoproteins after the second centrifugation step. Immunoreactivity of apoE on control
d < 1.02 g/ml chylomicron remnants after a second centrifugation was equal to that of the original d <1.02 g/ml
lipoproteins (Fig. 3). This observation demonstrates that
loss of 30% of the total apoE from the initial chylomicron
remnant does not change the immunoreactivity of the remaining apoE.
Hepatic lipase-treated chylomicron remnants collected
at d < 1.02 g/ml and 1.02 < d < 1.04 g/ml showed an enrichment of apoE relative to apoB when compared to d < 1.02
g/ml lipoproteins from control (untreated) incubations
(Table 4). This observation coupled with the lower content of free apoE in high density fractions (d 2 1.04 g/ml)
of hepatic lipase-treated lipoproteins (Table l), suggest
that chylomicron remnants exposed to hepatic lipase contain more tightly associated apoE than the untreated control lipoproteins.

1 .o

The major findings of this study are that 1) hydrolysis
of lipids by hepatic lipase leads to increased immunoreactivity of apoE on chylomicron remnants, and 2) hepatic
lipase hydrolyzes chylomicron remnant phospholipid and
triglyceride in a stepwise fashion in vitro. Evidence supporting sequential hydrolysis of phospholipid and
triglyceride was obtained from the isolation of a hydrolytic
intermediate depleted only of phospholipid, in addition to
a small remnant particle extensively depleted of phospholipid and triglyceride. Significant increases in apoE
immunoreactivity were observed in this dense subfraction

lipoproteins may be acted upon by hepatic lipase, bind
cell surface receptors, and then be rapidly internalized.
Increases in chylomicron remnant apoE exposure after
hydrolysis of remnant lipids by hepatic lipase may be the
key to increased binding of chylomicron rfx"nts to cell
surface ]ipoprotein receptors, Previous studies have
shown that rat lymph chylomicrons treated with hepatic
lipase are taken up more readily by liver than native
chylomicrons or chylomicron remnants treated solely with
lipoprotein lipase (51). Uptake of chylomicron remnants
by the liver is mediated by apoE binding to cell surface
receptors (5-9). Our data demonstrate that hepatic lipase
hydrolytic activity increases the immunoreactivity of
apoE, and may thereby enhance chylomicron remnant
clearance. The increased exposure of apoE may be essential for binding of the lipoprotein to cell surface receptors.
Further experimentation is necessary to test this hypothesis.
The chylomicron remnants used in our studies were the
product of lipolysis by lipoprotein lipase in vivo and
hepatic lipase in vitro. Previous studies have shown that
depletion of core and surface lipids by hydrolysis of
VLDL with bovine milk lipase increased immunoreactivity of apoB (52, 53); however, no change in im-
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Competition by d<1.02 g/ml lipoprotein isolated after one centrifugation step (closed symbols) and control d < 1.02 g/ml lipoprotein
isolated after mock hepatic lipase incubation and a second centrifugation
step (open symbols) with immobilized apoE for binding to soluble polyclonal goat anti-rat hepatic lipase IgG conjugated to horseradish peroxidase. Lipoprotein concentration is expressed as total apoE mass determined by ELISA of SDS-treated lipoproteins. BlBo values represent
absorbance of ELISA sample wells containing lipoprotein/absorbance of
wells containing only immobilized apoE. Data shown are averages of
duplicate values.

DISCUSSION

TABLE 4.

Experiment #

2
3
4

Mean

&

SD

Apolipoprotein E/apolipoprotein B molar ratios for lipoprotein fractions

Control
d<1.02 g / d
Fraction

Hepatic Lipase
Treatment
d < 1.02 g/ml
Fraction

Hepatic Lipase
Treatment
Dense Remnants
(1.02 < g < 1.04
dml)

1.44
1.32
1.58
1.50
1.46 rf. 0.11

1.83
2.04
1.93
1.54
1.84 & 0.21"

2.41
1.55
4.25
2.60
2.70 i 1.13h

"Differences between control d < 1.02 g/ml fractions and hepatic lipase treatment d C 1.02 g/ml fractions are significant at a level of P = 0.074 by Student's paired t-test.
'Control d<1.02 g/ml fractions vs. hepatic lipase treatment dense remnants; P = 0.094.
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Fig. 3.

of chylomicron remnants formed in vitro following extensive phospholipid and triglyceride hydrolysis.
The isolation of chylomicron remnants extensively
hydrolyzed by hepatic lipase in vivo has proven difficult to
accomplish. Chylomicrons are cleared very rapidly from
circulation (t112 = approximately 10 min) in rats (50).
Furthermore, difficulty in obtaining chylomicron remnants exposed to hepatic lipase in vivo may be related to
liver morphology and location of hepatic lipase in the
liver. Triglyceride-rich lipoproteins that are small enough
to pass through the fenestrae of liver endothelial cells become sequestered in the Space of Disse before interaction
with cell surface receptors on hepatocytes. Recent studies
have found a concentration of hepatic lipase in the Space
of Disse (E. J. Blanchette-Mackie and R. 0. Scow, personal communication) where it may be bound to heparan
sulfate proteoglycans (28) and come into contact with sequestered lipoproteins, Within the Space of Disse,
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